In Vitro and in Vivo Trypanocidal Effects of the Cyclopalladated Compound 7a, a Drug Candidate for Treatment of Chagas' Disease by Matsuo, Alisson L. et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2010, p. 3318–3325 Vol. 54, No. 8
0066-4804/10/$12.00 doi:10.1128/AAC.00323-10
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
In Vitro and In Vivo Trypanocidal Effects of the Cyclopalladated
Compound 7a, a Drug Candidate for Treatment
of Chagas’ Disease
Alisson L. Matsuo,1* Luis S. Silva,1 Ana C. Torrecilhas,2 Bruno S. Pascoalino,1 Thiago C. Ramos,1
Elaine G. Rodrigues,1 Sergio Schenkman,1 Antonio C. F. Caires,3 and Luiz R. Travassos1
Cell Biology Division, Department of Microbiology, Immunology and Parasitology, Federal University of Sa˜o Paulo, Sa˜o Paulo,
SP 04023-062, Brazil1; Department of Biological Sciences, Federal University of Sa˜o Paulo, Diadema, SP, Brazil2;
and Interdisciplinary Center of Biochemical Investigation, Mogi das Cruzes University,
Mogi das Cruzes, SP 08701-970, Brazil3
Received 8 March 2010/Returned for modification 13 April 2010/Accepted 7 May 2010
Chagas’ disease, a neglected tropical infection, affects about 18 million people, and 100 million are at risk.
The only drug available, benznidazole, is effective in the acute form and in the early chronic form, but its
efficacy and tolerance are inversely related to the age of the patients. Side effects are frequent in elderly
patients. The search for new drugs is thus warranted. In the present study we evaluated the in vitro and in vivo
effect of a cyclopalladated compound (7a) against Trypanosoma cruzi, the agent of Chagas’ disease. The 7a
compound inhibits trypomastigote cell invasion, decreases intracellular amastigote proliferation, and is very
effective as a trypanocidal drug in vivo, even at very low dosages. It was 340-fold more cytotoxic to parasites than
to mammalian cells and was more effective than benznidazole in all in vitro and in vivo experiments. The 7a
cyclopalladate complex exerts an apoptosis-like death in T. cruzi trypomastigote forms and causes mitochon-
drion disruption seen by electron microscopy.
Chagas’ disease, also known as American trypanosomiasis, is
an infection caused by the parasite Trypanosoma cruzi. Hu-
mans are infected by contaminated feces and urine of the
insect vector, transfusion with blood from infected patients,
oral transmission and contaminated food, and placental or
birth canal transmission (5). Inside humans, the parasite is
present as a circulating nonreplicative trypomastigote form
and inside cells as the replicative amastigote stage. The disease
is endemic from Mexico to Argentina, where 10% to 30% of
chronically infected persons develop cardiomyopathy and gas-
trointestinal problems (25). This neglected tropical disease
affects about 18 million people, and another 100 million are at
risk. Mortality ranges from 8% to 12% (31), with predicted
deaths of 50,000 people per year (10).
Nowadays, chemotherapy treatment of Chagas’ disease is
limited, being successful in the acute form, less so in the
chronic form, with severe side effects in elderly patients. No
successful vaccine has been developed so far (15). Prevention
is obtained by elimination of the insect vector and by increased
control in blood banks and congenital transmission. Benznida-
zole, a nitroimidazole derivative, has been used for the treat-
ment of acute and congenital T. cruzi infection. In a random-
ized, double-blind, placebo-controlled trial in a rural area in
Brazil where Chagas’ disease is endemic, a 60-day course of
benznidazole treatment of early chronic T. cruzi infection in
children was safe and 55.8% effective, with negative serocon-
version of specific antibodies (6). The 6-year follow-up of ad-
olescents enrolled in that trial showed successful chemother-
apy in 84.7% by seronegativity using chemiluminescent
enzyme-linked immunosorbent assay (ELISA) with a purified
trypomastigote mucin antigen (2). Benznidazole, however,
does not have all the conditions of an ideal drug, with its
efficacy and tolerance being inversely related to the age of the
patient (29). The other drug clinically available was Nifurti-
mox, but it has been discontinued from Bayer’s production
line. It is known that both drugs may increase the oxidative
stress causing parasite death (14). Generally, it is accepted that
new chemotherapeutic drugs should be developed for treat-
ment of Chagas’ disease together with improved methods to
determine a parasitological cure based on negative serology
(1).
In our laboratory we have studied cyclopalladated com-
plexes with biological activity. They are much more stable and
less toxic than other derivatives of palladium (II) (18) and were
able to inhibit cathepsin B (3). One of these compounds, called
complex 7a, showed specific in vitro and in vivo activities
against tumor cells, with no significant toxicity in animals, even
at high doses (20). The 7a compound causes anoikis and apop-
tosis of tumor cells (F. A. Serrano, D. C. Arruda, A. L. Matsuo,
L. S. Silva, S. Smaili, A. C. F. Caires, L. R. Travassos, and E. G.
Rodrigues, unpublished data), and its enantiomer is able to
oxidize mitochondrial proteins leading to permeabilization and
cytochrome c release (21).
Since the existing drugs against T. cruzi lead to oxidative
stress, we considered testing the 7a compound against the
parasite. T. cruzi, as well as other kinetoplastid protozoa, has a
single and large mitochondrion containing multiple copies of
DNA, forming a structure called a kinetoplast. The kinetoplas-
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tid mitochondrion also presents unique features regarding the
electron transport chain. For example, they contain a cyto-
chrome-independent alternative oxidase and have unique pro-
teins for kinetoplast maintenance, as topoisomerases, and also
an essential fatty acid pathway (22). Here we show that com-
pound 7a targets the parasite mitochondrion, inhibits amasti-
gote intracellular proliferation, and reduces experimental par-
asitemia and mortality with very low and nontoxic doses.
MATERIALS AND METHODS
Mice, cell line, parasites, and drugs. BALB/c female mice (8 to 10 weeks old)
were obtained from the CEDEME animal facility at UNIFESP. All animal
experiments and procedures were approved by the institution’s committee on the
ethical handling of laboratory animals. Trypomastigote forms (Y strain) were
obtained from the supernatant of infected LLCMK2 cells (ATCC CCL7) main-
tained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10%
of fetal bovine serum at 37°C in a humidified atmosphere with 5% CO2. For
mouse infections, trypomastigotes were routinely maintained by weekly intraper-
itoneal (i.p.) infection in BALB/c mice with 500 parasites, as described previously
(26). Benznidazole was a gift from Renato Mortara, Department of Parasitology,
UNIFESP.
Cyclopalladated complex 7a. The palladacycle compound 7a (Fig. 1) was
obtained from N,N-dimethyl-1-phenethylamine (DMPA), complexed to 1,2-eth-
ane-bis (diphenylphosphine) (DPPE) ligand. Binucleate complex 7a was fully
characterized as described by Rodrigues et al. (20) and shown to have antitumor
activity and no apparent toxicity in mice injected three times i.p. with doses of
240 nmol  kg1 of body weight of complex 7a/animal/week.
Parasite and mammalian cell drug cytotoxicity. Parasite killing levels for the
tested drugs were determined as described by Muelas-Serrano et al. (17). Briefly,
parasites recovered from the supernatants of disrupted infected cells were
counted in a Neubauer chamber and distributed in 96-well flat-bottom plates
(5  106 parasites per well). Drug 7a or benznidazole at 50 pmol  100
l1  well1 (500 nM) or 12.5 nmol  100 l1  well1 (125 M), respectively,
was added, and the time viability of parasites was measured by a 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay in a period up to
24 h.
Alternatively, for 50% inhibitory concentration (IC50) determination, wells
containing 2  104 parasites or LLCMK2 cells were incubated for 24 h with
different concentrations of 7a ranging from 5 pmol  100 l1  well1 (50 nM)
to 100 fmol  100 l1  well1 (1 nM) or 1 nmol  100 l1  well1 (10 M) to
50 pmol  100 l1  well1 (500 nM), respectively. Viable parasites were
counted in a Neubauer chamber, and viable cells were measured by the MTT
assay.
Cell invasion experiments. LLCMK2 cells (4  104) were plated onto 13-mm
glass coverslips inside a 24-well plate. After 24 h, cells were washed twice with
phosphate-buffered saline (PBS) and incubated with 5  106 trypomastigotes in
the presence of 7a ranging from 500 pmol  ml1  well1 (500 nM) to 500
fmol  ml1  well1 (500 pM) or 100 nmol  ml1  well1 (100 M) of ben-
znidazole in DMEM supplemented with 10% fetal bovine serum (FBS) for 2 h
at 37°C with 5% CO2. Cells were then washed five times with PBS to remove
extracellular trypomastigotes and further incubated in DMEM/10% FBS at 37°C
for two additional hours. Infected cells were examined for the presence of
internalized parasites by optical microscopy using standard Giemsa staining (9).
Drug effect on the proliferation of intracellular amastigotes. After inva-
sion, as described above, noninternalized parasites were washed away with
phosphate-buffered saline, and cells were incubated in the presence of 500
pmol  ml1  well1 (500 nM) of 7a or 50 nmol  ml1  well1 (50 M) of
benznidazole in DMEM containing 10% FBS. Fresh medium containing each
compound was replaced every 24 h. After 48 h, cells were fixed and stained with
Giemsa, and intracellular parasites counted by observation using an optical
microscope.
DNA degradation. Trypomastigotes released from LLCMK2 cultures (1 108)
were treated with 10 nmol  ml1 (10 M) of 7a in DMEM supplemented with
FBS at 37°C for 6 h. Parasites were centrifuged, resuspended in 500 l of 62.5
mM EDTA, 4% Triton X-100, 2.5 M LiCl2, and 50 mM Tris-HCl, pH 8.0
(TELT), and gently homogenized for 5 min. The same volume of chloroform-
phenol (1: 1) equilibrated in 0.1 M Tris-HCl, pH 8.0, was added, and phases were
separated by centrifugation. The aqueous phase was recovered, and the DNA
was precipitated with 2 volumes of ethanol and 0.1 M sodium acetate. The DNA
was recovered by centrifugation, washed with 70% ethanol, resuspended in
Milli-Q water with 20 g  ml1 of RNase, and incubated at 37°C for 1 h. DNA
integrity was observed by electrophoresis using 0.8% agarose gel in standard
Tris-acetate EDTA buffer.
Indirect immunofluorescence. Trypomastigotes (5  106 per ml) were treated
with 500 pmol  ml1 (500 nM) of 7a in DMEM supplemented with FBS at 37°C
for 30 min, then attached onto a glass slide for 5 min and subsequently fixed with
4% p-formaldehyde in PBS for 20 min. The slides were washed three times with
PBS, treated with Triton X-100 0.1% in PBS for 5 min, and then incubated
with 1% bovine serum albumin in PBS for 30 min. The slides were washed three
times with PBS, incubated with anti-dihydrolipoamide dehydrogenase (a mito-
chondrial matrix protein) antiserum (27) (kindly provided by Kevin Taylor,
University of East Anglia, United Kingdom) diluted in PBS for 1 h. Labeling was
detected with anti-rabbit IgG-Alexa Fluor 594 (Invitrogen) in the presence of
0.01 mM 4,6-diamidino-2-phenylindole (DAPI). Vectashield (Vector Laborato-
ries) was used for mounting, and the slides were visualized with a 100 oil
immersion objective (1.41 numerical aperture) in a Olympus BX61 microscope.
The images were acquired using cellMˆ software and processed by Blind 3D
deconvolution using the software AutoQuant X2 and Adobe Photoshop CS4.
Propidium iodide and annexin V staining. Trypomastigotes (1  107) were
treated with 250 pmol  ml1 (250 nM) of 7a in DMEM supplemented with FBS
at 37°C for 6 h and labeled for propidium iodide (PI) and annexin V using the
annexin V-FITC apoptosis detection kit (Sigma, MO) according to the manu-
facturer’s instructions. Data acquisition was performed using a FACSCalibur
flow cytometer (Becton Dickinson, CA), and data were analyzed with Cell Quest
software (Joseph Trotter, CA).
Transmission electron microscopy (TEM). Trypomastigotes (5  107) submit-
ted to treatment with 1 nmol  ml1 (1 M) of 7a in DMEM supplemented with
FBS at 37°C for 1 h were fixed for 1 h at room temperature with 2% formalde-
hyde and 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer at pH 7.2. The
fixed parasites were then decanted overnight on aclar film precoated with 0.01%
poly-L-lysine. The aclar film was washed three times with 0.1 M cacodylate, pH
7.2 (10 min each), incubated with 1% osmium tetroxide in the same buffer for 30
min at room temperature, washed with cacodylate buffer, and washed three times
with water. Subsequently the aclar was treated for 30 min with 0.4% uranyl
acetate for membrane contrast enhancement, gradually dehydrated in a series of
ethanol solutions, and embedded in Epon resin. Ultrathin sections were stained
with uranyl acetate and lead citrate, mounted on Formvar grids, and observed in
a JEOL 1200 EX II transmission electron microscope at 80 kV.
Animal infection. Blood parasitemia in the infected animal was quantified by
counting motile parasites in 10 l of fresh blood sample drawn from lateral tail
veins (26). Each mouse received a single dose i.p. of 200 nmol  kg1 of body
weight of the testing compound, or PBS as a control, 30 min before the inocu-
lation of 500 blood trypomastigotes. The parasitemia and animal survival were
recorded daily. In the therapeutic approach, infected mice were treated with
each compound for 13 consecutive days with up to 3 doses per day of 40
nmol  kg1 of body weight, with intervals of 4 h, starting 1 day after parasite
inoculation. Parasitemia was measured as described above, and survival was
followed every day until the 60th day postinfection. For histopathological anal-
ysis, animals were sacrificed on the 13th day postinfection. Experiments were
performed with 10 animals per group.
Preparation of tissues for histopathological analysis. The hematoxylin and
eosin (H&E) staining of paraffin sections was performed with heart, lung, blad-
der, spleen, intestine, and muscle tissues. The sections obtained from the exper-
imental and control groups were fixed in neutral buffered formalin (10% forma-
lin in PBS), dehydrated, and embedded in paraffin by a routine technique, and
semiserial sections of 5 m were stained with H&E. The results are expressed as
the mean number of amastigote nests per microscope field. The data presented
FIG. 1. Structure of the 7a compound [Pd2 (S()C2,N-DMPA)2
(m-DPPE)]Cl2.
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for each group are the mean  standard deviation (SD) of results for three
animals; 20 fields in 4 sections were counted in each tissue.
Statistical analyses. The Student t test was used throughout, except for with
the parasitemia and the survival curves, for which one-way analysis of variance
(ANOVA) and the Mantel-Cox test were employed, respectively.
RESULTS
Cyclopalladated 7a is highly toxic for T. cruzi trypomastig-
otes compared to mammalian cells in culture. To evaluate the
relative toxicity of the cyclopalladated compound 7a, we mea-
sured the IC50 for mammalian cells and trypomastigote forms
of the parasite. Cell culture-derived trypomastigotes (2  104)
were incubated for 24 h with different concentrations of 7a,
and the number of moving, refringent parasites was counted in
a Neubauer chamber. An IC50 of 15 nM was obtained (data not
shown). It is known that some metallic drugs have a nephro-
toxic effect. For this reason we used the mammalian kidney cell
lineage LLCMK2 for mammalian cell cytotoxic evaluation.
About 2  104 cells were distributed into a 96-well plate and
incubated with different concentrations of 7a. After 24 h, 7a
showed an IC50 of 5.1 M, measured by the MTT method
(data not shown). Thus, 7a drug affects preferentially the par-
asite, being effective at concentrations 340 times less than the
cytotoxic concentration for mammalian cells.
A trypanocide effect of drug 7a was observed at a much lower
concentration than that of benznidazole. Benznidazole is the
drug of choice for treatment of Chagas’ disease. To compare
the efficacies of drug 7a and benznidazole, cell-derived trypo-
mastigotes (5  106) were treated for 0, 2, 6, and 24 h with 7a
or benznidazole at 37°C in DMEM supplemented with 10%
FBS. As shown in Fig. 2, drug 7a at 50 pmol  100 l1  well1
(500 nM) causes a rapid decrease in parasite viability com-
pared with benznidazole (P  0.05). About 50% of the para-
sites died in the second hour of incubation. In contrast, a much
higher concentration of benznidazole, 12.5 nmol  100
l1  well1 (125 M), was required to obtain the same kill-
ing after 24 h of incubation.
Inhibition of T. cruzi cell invasion by 7a. Cell invasion by
trypomastigotes is a key step for establishment of T. cruzi
infection in the mammalian host. Therefore, we evaluated
whether 7a could prevent mammalian cell invasion in culture
by trypomastigotes. As shown in Fig. 3, drug 7a inhibited cell
invasion (P  0.05) at concentration as low as 5
pmol  ml1  well1 (5 nM) with 90% inhibition at 500
pmol  ml1  well1 (500 nM). This inhibitory effect cannot be
attributed to a direct parasite killing, since about 50% of par-
asites kept motility at 50 pmol  100 l1  well1 (500 nM) of
7a after 2 h of incubation. In contrast, benznidazole had no
effect on trypomastigote invasion, even at high concentrations,
probably due to its slow action.
Compound 7a prevents intracellular growth of amastigotes.
After cell invasion, trypomastigote forms transform into amasti-
gotes, which represent the intracellular replicative form of T.
cruzi. To verify whether 7a could have any effect against amasti-
gotes, preinfected cells were incubated with pmol  ml1  well1
(500 nM) of 7a or 50 nmol  ml1  well1 (50 M) of benznida-
zole for 48 h. After treatment, cells were stained with Giemsa and
observed by optical microscopy in order to evaluate the relative
number of infected cells and amastigotes per infected cell. As
shown in Fig. 4, both drugs at much different concentrations
significantly reduced (P  0.05) the relative number of infected
cells (Fig. 4A) with 50% parasites per infected cell (Fig. 4B).
Compound 7a induces an apoptosis-like parasite death. To
understand the mechanism by which compound 7a promotes
parasite death we compared the observed killing at 37°C with
the effect at 4°C (Fig. 5). We found that at 4°C much less
parasite lysis was observed, suggesting that metabolically active
parasites are required and that the effect of 7a does not occur
as a consequence of simple membrane destruction. Previous
work from our group suggests that compound 7a interacts with
mitochondria, causing a collapse in the cell extrusion of pro-
tons (20). Therefore, the parasites were stained by immuno-
fluorescence with a mitochondrial matrix marker after incuba-
tion with 7a. As shown in Fig. 5A to C, the mitochondrial
structure remains intact in control cells or parasites treated at
4°C, whereas parasites incubated with compound 7a at 37°C
FIG. 2. Time-dependent viability (MTT method) of 5  106 trypo-
mastigotes treated with compound 7a (50 pmol  100 l1  well1; 500
nM) or benznidazole (12.5 nmol  100 l1  well1; 125 M) during
24 h. , P  0.05.
FIG. 3. Drug 7a and benznidazole effects on parasite invasion of
mammalian cells. Parasites were plated on LLC-MK2 cells with com-
pound 7a or benznidazole for 2 h. Noninvading parasites were washed
away, and after 4 h, cells were stained with Giemsa. The number of
infected cells was determined by direct analysis under a light micro-
scope. , P  0.05.
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for 5 min showed morphological alterations in the mitochon-
drial structure (Fig. 5D). On prolonged incubation (30 min),
only those parasites incubated at 37°C died.
As death involving mitochondria is found in apoptosis, we
looked for other features of apoptotic death in the parasite.
DNA was extracted from 7a-treated and -untreated parasites,
and its integrity was analyzed by agarose gel electrophoresis.
Differently from the control, treated parasites showed DNA
FIG. 6. DNA degradation after trypomastigote treatment with
compound 7a for 6 h. A clear ladder pattern of degradation as found
in apoptosis was observed with treated parasites.
FIG. 4. Inhibition of amastigote growth. After 48 h treatment with
7a (500 pmol  ml1  well1 concentration at 500 nM) or benznida-
zole (50 nmol  ml1  well1; 50 M), infected cells were stained with
Giemsa and analyzed. (A) Percentage of infected cells after treatment;
(B) relative number of amastigotes per infected cell. , P  0.05.
FIG. 5. Effects of compound 7a on parasite mitochondrion at 4°C or 37°C. DNA staining was performed with DAPI (blue) and the
mitochondrion matrix marker with Alexa fluor 594 (red). (A) Nontreated trypomastigotes at 4°C; (B) 7a-treated trypomastigotes at 4°C;
(C) nontreated trypomastigotes at 37°C; (D) 7a-treated trypomastigotes at 37°C.
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degradation in a step pattern, suggestive of apoptosis (Fig. 6).
We then labeled parasites treated with 7a for a short period, to
avoid lysis, with annexin V to stain eventual phosphatidylserine
flipping to the membrane surface, which is another common
biochemical alteration observed in the apoptotic process. As
shown in Fig. 7, there is a clear increase in annexin V labeling
but no change in propidium iodide uptake in treated parasites
compared to control parasites as detected by fluorescence-
activated cell sorter (FACS), suggesting that labeling occurs
owing to the surface expression of the phospholipid.
Ultrastructural changes in the 7a-treated parasites. We de-
termined the ultrastructural disturbances in trypomastigote
forms caused by compound 7a using electron microscopy. Fig-
ure 8A shows a typical mitochondrion (M), nucleus (N), ki-
netoplast (K), and flagellum (F). In contrast, as shown in Fig.
8B and C, treated parasites showed mitochondrion swelling
(asterisk), formation of abnormal membrane structures inside
the organelle (black arrowhead), and atypical vacuoles (triangle).
This result corroborates the fluorescence microscopy in which the
morphological alterations of mitochondria are shown.
Preinjection of compound 7a protects mice from acute in-
fection. To verify the potential use of 7a compound for Chagas’
disease therapy, a single dose i.p. of 200 nmol of 7a per kg of
body weight was intraperitoneally administered 30 min before
mouse infection by highly virulent bloodstream forms of the T.
cruzi Y strain. As shown in Fig. 9, we observed a significant
delay in the mortality of mice pretreated with compound 7a
FIG. 7. Analysis of phosphatidylserine surface exposure by FACS,
in T. cruzi trypomastigotes treated with compound 7a for 6 h. The
ordinate represents PI-marked parasites, and abscissa corresponds to
the annexin V-positive parasites. (A) Nontreated parasites; (B) treated
parasites.
FIG. 8. Ultrastructural changes in 7a-treated trypomastigotes. (A) Control parasite: normal mitochondrion (M), nucleus (N), kinetoplast (K),
and flagellum (F); (B and C) treated parasites, showing mitochondrion swelling (asterisk), formation of abnormal membrane structures inside the
organelle (black arrows), and atypical vacuoles (triangle).
FIG. 9. Survival of pretreated mice. To evaluate a possible in vivo
drug effect, we treated female BALB/c mice with a single dose of 240
nmol  kg1 body weight of compound 7a or benznidazole 30 min
before infection with 500 trypomastigote forms. Percent survival is
shown; n  10. , P  0.01.
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(P  0.01). Specimens of heart, skeletal muscle, spleen, intes-
tine, lungs, bladder, and kidney collected on day 13 postinfec-
tion were examined for the presence of parasite nests by regular
H&E histopathology. The numbers of parasite nests decreased
for all observed tissues of treated animals, but only for the bladder
and heart were the differences statistically significant (P  0.05).
No parasites were seen in the spleen (Table 1).
Compound 7a is effective in the treatment of acute Chagas’
disease. As compound 7a proved to be effective against T. cruzi
infection when injected in mice prior to infection, we tested
whether it could eliminate the parasite from infected animals.
Three i.p. daily doses of 40 nmol of compound 7a or benznida-
zole per kg of body weight within 4-h intervals were adminis-
tered in mice 1 day after mouse infection with 500 trypomas-
tigote forms, until the 14th day. Maximal parasitemia and
animal mortality were significantly reduced (P  0.01) in 7a-
treated animals (Fig. 10A and B). Histopathological analysis of
tissues collected on day 13 postinfection still revealed the pres-
ence of amastigote nests in 7a-treated animals but at signifi-
cantly (P  0.05) lower levels than those for the saline control,
in the bladder, intestine, and heart, whereas benznidazole sig-
nificantly (P  0.05) decreased nests in the intestine (Table 2).
A higher dose, up to 200 nmol kg1, that was not toxic when
administered three times a week was not well tolerated when
injected daily for 10 days and showed no improvement in
animal survival (data not shown).
DISCUSSION
In the present work we demonstrate the potential of the
cyclopalladated compound 7a against T. cruzi infection. This
compound was previously shown to be effective against synge-
neic murine melanoma in vivo (20). It seems to target mito-
chondria of eukaryotic cells (F. A. Serrano et al., unpublished
data). Our experiments provide clear evidence that T. cruzi
invasive and intracellular proliferative forms are about 300
times more sensitive to compound 7a than mammalian cells.
Compound 7a destroys trypomastigotes probably by targeting
the mitochondrion, followed by DNA fragmentation and phos-
phatidylserine surface exposure, in a process that resembles
apoptosis of mammalian cells. It is well known that mitochon-
drial damage can initiate a series of events that lead cells to
apoptosis characterized by nuclear condensation and fragmen-
tation, caspase activation, and phosphatidyl serine cell surface
exposure, in an active process (28). The reason for this apop-
tosis-like process in a unicellular organism is still controversial.
In parasites like Leishmania, it has been proposed that a few
dead cells in the population stimulate infection (30). It has also
been proposed that T. cruzi insect forms are killed by comple-
ment through extensive free radical production by the mito-
chondrion and induction of a similar apoptotic-like mechanism
(12). Reports using venom from Bothrops jararaca (7) and
TABLE 1. Number of parasite nests in tissues from infected
mice pre-treated with 7aa
Tissue
Amastigote nests/20 fieldsb
Control
(n  3)
7a
(n  3)
Heart 28 ( 8.5) 4.8 ( 9)*
Bladder 56 ( 9.1) 8 ( 10)*
Lung 3 ( 4.4) 0.2 ( 0.45)
Intestine 1.7 ( 2.1) 0.2 (0.45)
Spleen 0 0
Muscle 0.67 ( 1.2) 0.2 ( 0.45)
a The sections of hematoxylin/eosin-stained tissues from mice injected i.p. with
7a at 200 nmol  kg1 body weight 30 min before infection with 500 bloodstream
trypomastigotes (Y strain) were scored for determination of the number of
parasite nests on the indicated tissues. *, P  0.05.
b Values are means standard deviations from 20 fields; magnification,400.
FIG. 10. Survival of acutely infected mice. One day after infection,
animals were treated with three doses of 40 nmol  kg1 body weight of
each drug per day until the 14th day. (A) Measurement of peak
parasitemia; (B) percent mouse survival in the control, benznidazole,
and 7a groups (n  10). , P  0.05.
TABLE 2. Histopathological analysis of tissuesa
Tissue
Amastigote nests/20 fieldsb
Control (n  5) Bz (n  5) 7a (n  4)
Heart 15.7 ( 4.6) 12.3 ( 5.0) 5.3 ( 4.6)*
Bladder 54.7 ( 17.9) 36.7 ( 5.5) 4.7 ( 4.5)*
Lung 1.3 (1.5) 0 0.3 ( 0.58)
Intestine 21.5 ( 0.7) 0.67 ( 1.2)* 0*
Spleen 4.7 ( 3.2) 2.3 ( 3.2) 0.67 ( 1.2)
Muscle 0 0 0
a The sections of hematoxylin/eosin-stained tissues from mice treated i.p. with
three doses per day of 7a at 40 nmol  kg1 body weight during 13 days after
infection with 500 bloodstream trypomastigotes (Y strain) were scored for the
number of parasite nests on the indicated tissues. *, P  0.05.
b Values are means standard deviations from 20 fields; magnification,400.
Bz, benznidazole.
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aromatic diamidines (8) also promoted a similar apoptosis-like
death of T. cruzi.
The distinctive mitochondrion of the parasite could explain
its increased susceptibility, with an IC50 340-fold less than that
in mammalian cells. Moreover, compound 7a acts very quickly
on trypomastigotes, unlike benznidazole, which, even at high
concentrations, may take more than 24 h to kill the parasite.
The inefficiency of benznidazole with the Y strain infection
may be explained by the partial resistance of this strain (16)
and was confirmed here, as even a single dose of 400
nmol  kg1 body weight of benznidazole had minimal effect.
As it has been proposed that benznidazole toxicity for T. cruzi
is due to oxidative stress generated preferentially in the para-
site (19), compound 7a could easily circumvent the resistance
mechanism.
Recently, NO-liberating drugs have been tested against T.
cruzi with successful in vivo results, leading to 60 to 80% sur-
vival and even 100% survival of infected mice in combination
with benznidazole (11, 23, 24). In vitro, all these drugs were
active, with IC50s of 52 M. In comparison, compound 7a
was even more effective with a very low IC50. Probably, using
other treatment protocols or drug combinations, the effective-
ness of compound 7a could be further improved to achieve
100% survival of infected animals.
The inhibition of cell invasion by 7a does not appear to occur
as a consequence of trypomastigote death. The most probable
explanation for this effect is that cyclopalladated compounds
may directly inhibit cysteine proteases by direct oxidation of
the catalytic domain (4). One of these enzymes is T. cruzi
cruzain, which is important for parasite invasion (13).
Previous studies have shown that compound 7a was used in
cancer therapy and was not toxic in mice, even at 240
nmol  kg1 body weight, injected three times a week. We
performed preliminary analysis of acute administration of a
4,000-nmol  kg1 single dose, i.p., and found that it was not
lethal to mice (data not shown). Presently, the therapeutic in
vivo test showed that compound 7a was able to significantly
reduce the parasitemia and the number of parasite nests in the
bladder, heart, and intestine (P  0.05), with 80% animal
survival after 60 days of infection (P  0.01). It is important to
note that the treatment terminated on day 14 and that the first
7a-treated mouse died after 34 days of infection, while both
PBS- and benznidazole-treated groups of mice were all dead
on day 22. We report here on a promising chemotherapeutic
approach against T. cruzi that might possibly be extended to all
kinetoplastidae because the cyclopalladated compound rapidly
disrupts the mitochondrion. This compound was demonstrated
to have a fast antiparasite effect, decreasing its viability and
invasion capacity and leading to an apoptosis-like death. In
preclinical assays, it was very effective in protecting 80% of
treated animals. Due to its high efficacy in vivo, it could be an
alternative treatment for Chagas’ disease. Further studies on
the treatment protocols may help us to improve the compound
efficacy in the treatment of experimental trypanosomiasis.
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